Protocol Ledger

NCT05694260 · Phase II · COMPLETED

A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)

Interventional Phase II clinical trial protocol NCT05694260 sponsored by Esperion Therapeutics in Cardiovascular and Thrombosis, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-01-12 Enrollment: 31 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05694260
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)31 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05694260
Protocol FieldVerified Registry Value
NCT IdentifierNCT05694260
Consolidated Lead SponsorEsperion Therapeutics
Therapeutic Condition CohortCardiovascular and Thrombosis
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment31 participants (ACTUAL)
Registered Start Date2023-01-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Cardiovascular and Thrombosis Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI